PDF(Pubmed)
Abstract：
UNASSIGNED: The difficulties in attaining effective antibiotic therapy arising from the multidrug resistance of Gram-negative bacilli compel the exploration of new possibilities for synergistic interactions among existing antibiotics.
UNASSIGNED: An analysis was conducted to assess the efficacy of two antibiotic therapy regimens in the treatment of infections caused by Klebsiella pneumoniae strains producing carbapenemases (MBL). Two patient groups were considered: Group A - individuals in whom the treatment of infection involved the application of ceftazidime-avibactam in combination with aztreonam. Group B comprised patients subjected to an alternative antibiotic therapy regimen.
UNASSIGNED: In the group subjected to the treatment regimen involving ceftazidime-avibactam and aztreonam, as compared to alternative antibiotic combinations, a statistically lower mortality rate during the course of treatment and a faster clinical response to the administered therapy were evident.
UNASSIGNED: The results obtained may be applicable to routine in vitro assays performed and serve as valuable guidance for the potential utilization of the positive effect of antibiotic therapy through the synergy between ceftazidime-avibactam and aztreonam. The selection of antibiotics employed in the therapy of invasive infections caused by K. pneumoniae influences the ultimate treatment outcome.
UNASSIGNED: An analysis was conducted to assess the efficacy of two antibiotic therapy regimens in the treatment of infections caused by Klebsiella pneumoniae strains producing carbapenemases (MBL). Two patient groups were considered: Group A - individuals in whom the treatment of infection involved the application of ceftazidime-avibactam in combination with aztreonam. Group B comprised patients subjected to an alternative antibiotic therapy regimen.
UNASSIGNED: In the group subjected to the treatment regimen involving ceftazidime-avibactam and aztreonam, as compared to alternative antibiotic combinations, a statistically lower mortality rate during the course of treatment and a faster clinical response to the administered therapy were evident.
UNASSIGNED: The results obtained may be applicable to routine in vitro assays performed and serve as valuable guidance for the potential utilization of the positive effect of antibiotic therapy through the synergy between ceftazidime-avibactam and aztreonam. The selection of antibiotics employed in the therapy of invasive infections caused by K. pneumoniae influences the ultimate treatment outcome.
摘要：
■由于革兰氏阴性杆菌的多药耐药性而难以获得有效的抗生素治疗，这迫使人们探索现有抗生素之间协同相互作用的新可能性。
进行了一项分析，以评估两种抗生素治疗方案在治疗由产生碳青霉烯酶（MBL）的肺炎克雷伯菌菌株引起的感染中的功效。考虑了两个患者组：A组-感染治疗涉及头孢他啶-阿维巴坦联合氨曲南的应用的个体。B组包括接受替代抗生素治疗方案的患者。
■在接受头孢他啶-阿维巴坦和氨曲南治疗方案的组中，与替代抗生素组合相比，在治疗过程中统计学上较低的死亡率和对给药治疗更快的临床反应是明显的.
■获得的结果可能适用于进行的常规体外测定，并为通过头孢他啶-阿维巴坦和氨曲南之间的协同作用潜在利用抗生素治疗的积极作用提供有价值的指导。选择用于治疗肺炎克雷伯菌引起的侵袭性感染的抗生素会影响最终的治疗结果。
进行了一项分析，以评估两种抗生素治疗方案在治疗由产生碳青霉烯酶（MBL）的肺炎克雷伯菌菌株引起的感染中的功效。考虑了两个患者组：A组-感染治疗涉及头孢他啶-阿维巴坦联合氨曲南的应用的个体。B组包括接受替代抗生素治疗方案的患者。
■在接受头孢他啶-阿维巴坦和氨曲南治疗方案的组中，与替代抗生素组合相比，在治疗过程中统计学上较低的死亡率和对给药治疗更快的临床反应是明显的.
■获得的结果可能适用于进行的常规体外测定，并为通过头孢他啶-阿维巴坦和氨曲南之间的协同作用潜在利用抗生素治疗的积极作用提供有价值的指导。选择用于治疗肺炎克雷伯菌引起的侵袭性感染的抗生素会影响最终的治疗结果。
